NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.

Employees

2,200

Sector

Healthcare Facilities & Services

Calendar

25/02 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
23/26/23	12.81 $	-1.23%	30,25,283
22/26/22	12.97 $	+2.21%	16,83,594
21/26/21	12.69 $	+0.40%	18,44,913
20/26/20	12.64 $	-1.17%	14,86,186
16/26/16	12.79 $	-0.31%	59,43,083

Delayed Quote Nasdaq, January 24, 2026 at 02:30 am IST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

12.81USD

Average target price

14.43USD

Spread / Average Target

+12.64%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 02:30:00 24/01/2026 am IST			5-day change	1st Jan Change
12.81 ^USD	-1.23%		+0.16%	+8.93%

14/01	NeoGenomics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 05:15 PM
13/01	NeoGenomics, Inc. Announces Chief Financial Officer Changes	CI

Capitalization	165.75Cr 140.97Cr 130.66Cr 122.1Cr 227.62Cr 15TCr 241.26Cr 1.49TCr 592.84Cr 7.19TCr 621.5Cr 608.78Cr 26TCr	P/E ratio 2025 *	-14.2x	P/E ratio 2026 *	-22.3x
Enterprise value	165.75Cr 140.97Cr 130.66Cr 122.1Cr 227.62Cr 15TCr 241.26Cr 1.49TCr 592.84Cr 7.19TCr 621.5Cr 608.78Cr 26TCr	EV / Sales 2025 *	2.29x	EV / Sales 2026 *	2.08x
Free-Float	98.72%	Yield 2025 *	-	Yield 2026 *	-

14/01	NeoGenomics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 05:15 PM
13/01	NeoGenomics, Inc. Announces Chief Financial Officer Changes	CI
13/01	NeoGenomics, Inc. Announces Executive Changes	CI
13/01	NeoGenomics, Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2025	CI
12/01	NeoGenomics Expects Q4 Revenue of $190 Million; Names Abhishek Jain as CFO	MT
30/12	Neogenomics appoints diagnostics and lab services industry veteran John P. "Jack" Kenny to its board of directors	RE
30/12	NeoGenomics, Inc. Announces Resignation of Dr. Alison L. Hannah as a Director, Effective December 31, 2025	CI
30/12	NeoGenomics, Inc. Appoints John P. ?Jack? Kenny to Its Board of Directors	CI
15/12	NeoGenomics Says Natera Withdraws Appeal in Patent Case	MT
15/12	Neogenomics announces that Natera has voluntarily withdrawn its appeal in ongoing RaDaR patent litigation	RE
10/12	NeoGenomics, Inc. to Present New ctDNA Research at SABCS 2025	CI
08/12	NeoGenomics, Inc. to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025	CI
30/25/30	NeoGenomics, Inc. to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors	CI

30/25/30	BTIG Research Downgrades NeoGenomics to Neutral From Buy	MT
18/25/18	BofA Securities Adjusts NeoGenomics Price Target to $8 From $10, Maintains Neutral Rating	MT
15/25/15	Guggenheim Initiates Coverage on NeoGenomics With Neutral Rating	MT
30/25/30	Leerink Partners Downgrades NeoGenomics to Market Perform From Outperform, Lowers Price Target to $9 From $25	MT
29/25/29	Top Midday Decliners	MT

NeoGenomics, Inc. Share Price

Equities

NEO

US64049M2098

Healthcare Facilities & Services

Valuation: NeoGenomics, Inc.

Chart: NeoGenomics, Inc.

Latest news: NeoGenomics, Inc.

Last Transcript: NeoGenomics, Inc.

Analysts' recommendations: NeoGenomics, Inc.

Press Releases: NeoGenomics, Inc.

News in other languages: NeoGenomics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: NeoGenomics, Inc.

Medical & Diagnostic Laboratories

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

14/01	NeoGenomics : at JP Morgan Healthcare Conference 2026	PU
12/01	NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue	BU
05/01	NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference	BU
30/12	NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors	BU
15/12	NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation	BU

02/25/02	Momentum Picks 1T 2025: 5 valores para el invierno
02/25/02	Momentum Picks Q1 2025: vijf aandelen voor de winter
02/25/02	Momentum Picks Q1 2025: 5 Aktien für den Winter
02/25/02	Momentum Picks Q1 2025: 5 titoli per l’inverno
02/25/02	Momentum Picks T1 2025 : 5 actions pour l'hiver

1 day	-1.23%
1 week	+0.16%
Current month	+8.93%
1 month	+3.14%
3 months	+22.58%
6 months	+93.80%
Current year	+8.93%

1 week	12.28	13.29
1 month	11.42	13.74
Current year	11.42	13.74
1 year	4.72	15.32
3 years	4.72	21.22
5 years	4.72	61.57
10 years	4.72	61.57

Manager	Title	Age	Since
Anthony Zook CEO	Chief Executive Officer	65	01/04/2025
Jeffrey Sherman DFI	Director of Finance/CFO	60	07/12/2022
Warren Stone PSD	President	53	01/04/2025

Director	Title	Age	Since
Lynn Tetrault CHM	Chairman	63	07/10/2021
Stephen Kanovsky BRD	Director/Board Member	63	19/07/2017
Michael Kelly BRD	Director/Board Member	69	15/07/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
NEOGENOMICS, INC.	-1.23%	+0.16%	-12.62%	+7.29%	165.75Cr
NATERA, INC.	-0.55%	+4.47%	+40.60%	+458.82%	3.34TCr
SONIC HEALTHCARE LIMITED	-0.77%	+0.39%	-16.25%	-25.93%	792.49Cr
RADNET, INC.	+0.27%	+3.07%	+12.66%	+252.29%	565.48Cr
GENEDX HOLDINGS CORP.	-0.52%	-6.23%	+30.50%	+673.41%	292.95Cr
DR. LAL PATHLABS LIMITED	-2.93%	-1.54%	-4.34%	+27.80%	250.34Cr
DIAN DIAGNOSTICS GROUP CO.,LTD.	+3.68%	+8.23%	+159.24%	-0.51%	240.03Cr
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	+2.01%	+2.85%	+36.25%	-61.31%	223.08Cr
ULTRAGREEN.AI LIMITED	-2.33%	+2.44%	-	-	185.07Cr
FLEURY S.A.	+4.68%	+8.68%	+46.59%	+20.85%	172.74Cr
Average	+0.23%	+1.83%	+32.51%	+150.30%	622.95Cr
Weighted average by Cap.	-0.27%	+2.78%	+31.44%	+306.16%

	2025 *	2026 *
Net sales	73Cr 62Cr 57Cr 53Cr 100Cr 6.66TCr 105.56Cr 653.36Cr 259.39Cr 3.15TCr 271.92Cr 266.36Cr 11TCr	80Cr 68Cr 63Cr 59Cr 109.27Cr 7.31TCr 115.82Cr 716.85Cr 284.59Cr 3.45TCr 298.35Cr 292.25Cr 13TCr
Net income	-12Cr -9.82Cr -9.1Cr -8.5Cr -16Cr -1.06TCr -17Cr -103.97Cr -41Cr -500.62Cr -43Cr -42Cr -1.82TCr	-7.47Cr -6.35Cr -5.89Cr -5.5Cr -10Cr -686.44Cr -11Cr -67Cr -27Cr -324.1Cr -28Cr -27Cr -1.18TCr
Net Debt	-	-